Rituximab in ANCA-Associated Vasculitis

被引：43

作者：

Hassan, Romina I. ^{[1
]}

Gaffo, Angelo L. ^{[2
,3
]}

机构：

[1] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina

[2] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA

[3] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA

来源：

CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 02期

关键词：

Rituximab; Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA); WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE; MANAGEMENT; RELAPSES;

D O I：

10.1007/s11926-017-0632-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.

引用

页数：8

共 50 条

[21] Complications of therapy for ANCA-associated vasculitis
Smith, Rona
RHEUMATOLOGY, 2020, 59 : 74 - 78
[22] Renal disease in ANCA-associated vasculitis
Vanhille, Philippe
Vrigneaud, Laurence
Quemeneur, Thomas
PRESSE MEDICALE, 2012, 41 (03): : 247 - 253
[23] Extending the Indications for Rituximab in ANCA-Associated Vasculitis
Jayne, David
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) : 1839 - 1840
[24] B-cell treatment in ANCA-associated vasculitis
Karras, Alexandre
Lazareth, Helene
Chauvett, Sophie
RHEUMATOLOGY, 2020, 59 : 68 - 73
[25] Recommendations on the use of rituximab for ANCA-associated vasculitis
Gause, A. M.
Rubbert-Roth, A.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2014, 73 (03): : 287 - 289
[26] Rituximab for ANCA-associated vasculitis: The UK experience
Jayne, David
PRESSE MEDICALE, 2013, 42 (04): : 532 - 534
[27] Rituximab for ANCA-associated vasculitides
Guillevin, L.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S118 - S121
[28] ANCA-associated vasculitis
Krasselt, Marco L.
Holle, Julia U.
INNERE MEDIZIN, 2022, 63 (09): : 947 - 960
[29] Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Jones, Rachel B.
Tervaert, Jan Willem Cohen
Hauser, Thomas
Luqmani, Raashid
Morgan, Matthew D.
Peh, Chen Au
Savage, Caroline O.
Segelmark, Marten
Tesar, Vladimir
van Paassen, Pieter
Walsh, Dorothy
Walsh, Michael
Westman, Kerstin
Jayne, David R. W.
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) : 211 - 220
[30] Emerging targeted therapies in ANCA-associated vasculitis
Jayne, David
RHEUMATOLOGY, 2025, 64 : i15 - i18

← 1 2 3 4 5 →